title: Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert Delphi analysis.
abstract: OBJECTIVE
  The aim of this study was to investigate experts' opinions regarding the extent to which the introduction of pretesting for polymorphism of serotonin transporter promoter region (5-HTTLPR) as a routine intervention in clinical practice would lead to better clinical outcomes for depression patients.
  
  
  METHODS
  Using an internet survey system, authors of clinical studies addressing the topic of association of 5-HTTLPR genotyping with antidepressant response were contacted to participate in a Delphi study.
  
  
  RESULTS
  Responses from 12 experts were used for the final analysis. According to the participants, the introduction of 5-HTTLPR genotyping will lead to 33.8, 48.2, 57.8, and 65.1% of patients reaching remission at 1, 2, 3, and 6 months, respectively.
  
  
  CONCLUSIONS
  According to experts, application of 5-HTTLPR pretreatment genotyping might influence remission; however, the estimated remission rates with genotyping at first sight do not appear to be superior to existing practice, i.e. without genotyping. It is anticipated that a combination of 5-HTTLPR testing with other genomic variables, which have yet to be determined, and compliance measurements can improve clinical outcomes in the future. At present, the introduction of 5-HTTLPR genotyping is expected to be used only in special situations.
authors.affiliation: Department of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, University of Copenhagen, Copenhagen, Denmark. soe@farma.ku.dk
authors.forename: S
authors.initials: S
authors.lastname: Oestergaard
authors.forename: C
authors.initials: C
authors.lastname: Møldrup
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D003661:Decision Support Techniques; D003697:Delphi Technique; D003866:Depressive Disorder / Q000188:drug therapy / Q000235:genetics*; D005838:Genotype; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D050486:Serotonin Plasma Membrane Transport Proteins